Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032. doi: 10.1182/blood-2011-01-293050
   PubMed Web of Science ®Google Scholar
• Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter’s syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol. 1995;147(1):207–216.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99(3):815–821. doi: 10.1182/blood.V99.3.815
   PubMed Web of Science ®Google Scholar
• Jevremovic D, Dronca RS, Morice WG, et al. CD5+ B-cell lymphoproliferative disorders: beyond chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res. 2010;34(9):1235–1238. doi: 10.1016/j.leukres.2010.03.020
   PubMed Web of Science ®Google Scholar
• Gary-Gouy H, Bruhns P, Schmitt C, et al. The pseudo-immunoreceptor tyrosine-based activation motif of CD5 mediates its inhibitory action on B-cell receptor signaling. J Biol Chem. 2000;275(1):548–556. doi: 10.1074/jbc.275.1.548
   PubMed Web of Science ®Google Scholar
• Gary-Gouy H, Harriague J, Bismuth G, et al. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood. 2002;100(13):4537–4543. doi: 10.1182/blood-2002-05-1525
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohno T, Oka K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol. 1999;105(4):1133–1139. doi: 10.1046/j.1365-2141.1999.01513.x
   PubMed Web of Science ®Google Scholar
• Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999;13(9):1441–1447. doi: 10.1038/sj.leu.2401487
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195–1202. doi: 10.3324/haematol.12810
   PubMed Web of Science ®Google Scholar
• Hyo R, Tomita N, Takeuchi K, et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol. 2010;28(1):27–32.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Tamaru JI, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010;21(10):2069–2074. doi: 10.1093/annonc/mdq057
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang HY, Zhong FL, et al. Clinical analysis of 10 patients with de novo CD5 positive diffuse large B cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(2):399–402.
   PubMedGoogle Scholar
• Tzankov A, Leu N, Muenst S, et al. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. J Hematol Oncol. 2015;8(70).
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Yamaguchi M, Suzuki R, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601–1607. doi: 10.1093/annonc/mdq627
   PubMed Web of Science ®Google Scholar
• Alinari L, Gru A, Quinion C, et al. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91(4):395–399. doi: 10.1002/ajh.24299
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ma XB, Jiang J, et al. CD5 expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Zhonghua Bing Li Xue Za Zhi. 2012;41(3):156–160.
   PubMedGoogle Scholar
• Zang L, Zhang HY, Zhong FL, et al. Clinical analysis of CD5 + diffuse large B-cell lymphoma. Shandong Med J. 2015;55(37):12–14.
   Google Scholar
• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009: 523–531. doi: 10.1182/asheducation-2009.1.523
   PubMedGoogle Scholar
• Hans CP., Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282. doi: 10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Chuang WY, Chang H, Shih LH, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch. 2015;467(5):571–582. doi: 10.1007/s00428-015-1845-1
   PubMed Web of Science ®Google Scholar
• Thakral B, Medeiros LJ, Desai P, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98(4):415–421. doi: 10.1111/ejh.12847
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Yamaguchi M, Imai H, et al. Gene expression profiling of diffuse large B-cell lymphomas supervised by CD5 expression. Int J Hematol. 2015;102(2):188–194. doi: 10.1007/s12185-015-1812-2
   PubMed Web of Science ®Google Scholar
• Xu-Monette Z, Tu M, Jabbar KJ, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015;6(8):5615–5633. doi: 10.18632/oncotarget.3479
   PubMedGoogle Scholar
• Jain P, Fayad LE, Rosenwald A, et al. Recent advances in de novo CD5+ diffuse large B cell lymphoma. Am J Hematol. 2013;88(9):798–802. doi: 10.1002/ajh.23467
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X, Liu Y, et al. Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: a promising response and review. Cancer Biol Ther. 2018;19(7):549–553. doi: 10.1080/15384047.2018.1449609
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma–a survey of 1693 patients treated in protocols of the German high-grade non-Hodgkin’s lymphoma study group (DSHNHL). Ann Oncol. 2007;18(1):149–157. doi: 10.1093/annonc/mdl327
   PubMed Web of Science ®Google Scholar
• Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129–133. doi: 10.1093/annonc/mdh013
   PubMed Web of Science ®Google Scholar
• Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008;19(11):1921–1926. doi: 10.1093/annonc/mdn392
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101(11):4279–4284. doi: 10.1182/blood-2002-11-3442
   PubMed Web of Science ®Google Scholar
• Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma. 2007;48(6):1102–1109. doi: 10.1080/10428190701344881
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284–4289. doi: 10.1182/blood-2003-02-0542
   PubMed Web of Science ®Google Scholar
• Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
   Google Scholar
• Tokuhira M, Watanabe R, Iizuka A, et al. De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation. Am J Hematol. 2007;82(2):162–167. doi: 10.1002/ajh.20786
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407. doi: 10.1056/NEJMoa1801445
   PubMed Web of Science ®Google Scholar